Catalyst
Slingshot members are tracking this event:
Shire’s SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults who have Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
- Source Link:
- https://www.shire.com/newsroom/2016/july/7zve23
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SHPG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Volixibat, Fast Track Designation, Nonalcoholic Steatoheatitis, Liver Fibrosis
